TapImmune
TapImmune develops immunotherapeutics to treat cancers, infectious diseases, autoimmune disorders, and transplant tissue rejection.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | $3.1m | Post IPO Equity | |
| Total Funding | 000k | ||
TapImmune is a biotechnology company focused on developing innovative immunotherapies for the treatment of cancer and infectious diseases. The company operates in the biopharmaceutical market, targeting both healthcare providers and patients who require advanced therapeutic solutions. TapImmune's business model revolves around the research, development, and commercialization of proprietary vaccine technologies that enhance the body's immune response to combat serious illnesses. Revenue is generated through partnerships, licensing agreements, and the eventual sale of approved therapies. The company's core competencies include cutting-edge vaccine platforms, robust clinical trial pipelines, and strategic collaborations with leading research institutions.
Keywords: immunotherapies, cancer, infectious diseases, vaccines, biotechnology, biopharmaceutical, healthcare, clinical trials, research, commercialization.